Core Viewpoint - Twist Bioscience (TWST) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on February 2, with a consensus estimate of a quarterly loss of $0.48 per share, reflecting a year-over-year change of +9.4% [3][11]. - Revenues are projected to reach $101.45 million, which is a 14.4% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial estimates during this period [4]. - The Most Accurate Estimate for Twist Bioscience is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.05%, suggesting a bearish outlook from analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from the consensus estimate, with positive readings being more reliable [8][9]. - Twist Bioscience currently holds a Zacks Rank of 2 (Buy), but the negative Earnings ESP complicates predictions of an earnings beat [11]. Historical Performance - In the last reported quarter, Twist Bioscience was expected to post a loss of $0.40 per share but actually reported a loss of $0.45, resulting in a surprise of -12.50% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [13]. Industry Comparison - Regeneron (REGN), another player in the biomedical and genetics industry, is expected to report earnings of $10.6 per share for the same quarter, indicating a year-over-year change of -12.2% and revenues of $3.82 billion, up 0.7% from the previous year [17][18]. - Regeneron has an Earnings ESP of +1.06% and a Zacks Rank of 1 (Strong Buy), suggesting a higher likelihood of beating the consensus EPS estimate [19].

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [3] - Stocks receive an alphabetic rating from A to F, with A indicating the highest potential for outperforming the market [4] Value Score - The Value Style Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [5] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings outlook changes, helping investors capitalize on upward or downward price movements [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [7] Zacks Rank and Style Scores - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in portfolio creation [8] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [9] Stock Selection Strategy - For optimal returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with a 3 (Hold) rank should also have Style Scores of A or B to maximize upside potential [10] Company Spotlight: Incyte Corporation - Incyte Corporation, based in Wilmington, DE, is a biopharmaceutical company engaged in developing proprietary therapeutics [12] - Currently rated 3 (Hold) with a VGM Score of A, Incyte has a Momentum Style Score of A and has seen a 1.9% increase in shares over the past four weeks [12][13] - The earnings estimate for fiscal 2025 has been revised upwards, with the Zacks Consensus Estimate now at $6.88 per share, reflecting an average earnings surprise of +14.4% [13]

Core Viewpoint - The Zacks Style Scores provide a framework for investors to evaluate stocks based on value, growth, and momentum, enhancing the decision-making process for stock selection [2][3][7]. Summary by Category Zacks Style Scores - The Zacks Style Scores rate stocks using a grading system from A to F, with A being the highest score indicating a better chance of outperforming the market [3]. - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6]. Value Score - The Value Score helps investors identify undervalued stocks by analyzing financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3]. Growth Score - The Growth Score emphasizes a company's financial health and future growth potential, considering projected and historical earnings, sales, and cash flow [4]. Momentum Score - The Momentum Score assists investors in capitalizing on stock price trends, utilizing metrics like one-week price changes and monthly earnings estimate changes [5]. VGM Score - The VGM Score combines the three Style Scores to identify stocks with attractive value, strong growth forecasts, and promising momentum, serving as a useful indicator alongside the Zacks Rank [6]. Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7][8]. Stock Example: Stryker (SYK) - Stryker is a leading medical technology company, generating approximately 60% of its sales from MedSurg & Neurotechnology and 40% from Orthopaedics, with about 75% of revenue coming from the U.S. market [12]. - Stryker holds a 3 (Hold) rating on the Zacks Rank and has a VGM Score of B, with a Momentum Style Score of B, indicating potential for investors [13][14].

Core Viewpoint - The Progressive Corporation (PGR) is anticipated to show improvements in both revenue and earnings for the fourth quarter of 2025, with a revenue estimate of $21.9 billion, reflecting a 7.9% year-over-year growth [1][9]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for PGR's fourth-quarter revenues is $21.9 billion, indicating a 7.9% increase from the previous year [1][9]. - The consensus estimate for earnings per share (EPS) is $4.44, which represents an 8.8% year-over-year growth [2][9]. Earnings Surprise History - Progressive has a mixed earnings surprise history, beating the Zacks Consensus Estimates in two of the last four quarters, with an average surprise of 1.84% [3]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for Progressive, as it lacks the necessary combination of a positive Earnings ESP and a favorable Zacks Rank [4]. - PGR has an Earnings ESP of +0.69%, with the Most Accurate Estimate at $4.47, slightly above the consensus estimate of $4.44 [5]. Factors Influencing Q4 Results - Revenue growth is expected to be driven by higher premiums, increased net investment income, and stronger fees and service revenues, particularly in personal auto products and commercial lines [6]. - The Zacks Consensus Estimate for net premiums earned is $20.9 billion, indicating a 9.3% increase from the previous year [7]. Business Performance Insights - The personal auto business is likely to benefit from growth in new and renewal applications, supported by increased advertising spend and competitive pricing [8]. - The consensus estimate for personal auto policies in force is 26.1 million [8]. Financial Metrics - PGR's combined ratio is expected to improve to 88.6%, aided by prudent underwriting practices and mild catastrophe losses [9][11]. - The consensus estimate for pretax net realized gains on securities is $84.5 million, reflecting a significant increase of 22% from the previous year [10].

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed along ...

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores provide a framework for evaluating stocks based on value, growth, and momentum, aiding investors in selecting securities likely to outperform the market [2] Zacks Style Scores Overview - Stocks are rated A, B, C, D, or F based on their value, growth, and momentum characteristics, with higher scores indicating a better chance of outperforming the market [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - The Value Style Score focuses on identifying undervalued stocks using metrics like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Style Score assesses a company's financial health and future outlook through projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Style Score evaluates trends in stock prices and earnings estimates to identify favorable buying opportunities [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors seeking attractive value, growth, and momentum [6] Zacks Rank Integration - The Zacks Rank utilizes earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [8] Investment Strategy - For optimal returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while 3 ranked stocks should also have high Style Scores to maximize upside potential [9][10] Company Spotlight: Bayer Aktiengesellschaft - Bayer AG, headquartered in Leverkusen, Germany, is rated 2 (Buy) on the Zacks Rank with a VGM Score of A and a Value Style Score of A, indicating strong valuation metrics [11] - The company has seen two analysts raise their earnings estimates for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.10 to $1.43 per share and an average earnings surprise of +18.5% [12]

Company Performance - Allogene Therapeutics (ALLO) has returned 25.6% year-to-date, significantly outperforming the average gain of 7.7% in the Medical sector [4] - The Zacks Consensus Estimate for ALLO's full-year earnings has increased by 3%, indicating improved analyst sentiment and earnings outlook [4] - Allogene Therapeutics holds a Zacks Rank of 2 (Buy), suggesting it is poised for potential outperformance in the near term [3] Industry Context - Allogene Therapeutics is part of the Medical - Biomedical and Genetics industry, which consists of 452 stocks and currently ranks 87 in the Zacks Industry Rank [6] - The average gain for stocks in the Medical - Biomedical and Genetics industry this year is 21.4%, indicating that ALLO is performing better than its industry peers [6] - Alzamend Neuro, Inc. (ALZN), another stock in the same industry, has also shown strong performance with a year-to-date return of 20.9% and a Zacks Rank of 2 (Buy) [5][6]

Group 1: Company Performance - Callaway Golf (CALY) has returned approximately 33.7% since the beginning of the calendar year, significantly outperforming the Consumer Discretionary sector, which has returned an average of -0.1% year-to-date [4] - The Zacks Consensus Estimate for CALY's full-year earnings has increased by 161% over the past quarter, indicating improving analyst sentiment and a positive earnings outlook [3] - Callaway Golf is currently ranked 1 (Strong Buy) in the Zacks Rank system, which emphasizes earnings estimates and revisions [3] Group 2: Industry Context - Callaway Golf belongs to the Leisure and Recreation Products industry, which includes 24 individual stocks and is currently ranked 89 in the Zacks Industry Rank, with an average gain of 6.8% this year [5] - In comparison, Ralph Lauren, another stock in the Consumer Discretionary sector, has a year-to-date return of 3.9% and belongs to the Textile - Apparel industry, which is ranked 63 and has declined by 12.1% this year [4][6]

Group 1 - Westport Innovations (WPRT) has shown strong year-to-date performance, gaining approximately 38.9%, significantly outperforming the average gain of 13% in the Auto-Tires-Trucks sector [4] - The Zacks Rank for Westport Innovations is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for WPRT's full-year earnings has increased by 4.8% over the past three months, reflecting improved analyst sentiment [4] Group 2 - Westport Innovations is part of the Automotive - Original Equipment industry, which has underperformed with an average loss of 2.4% this year, highlighting WPRT's relative strength [6] - Xos, Inc. (XOS) is another stock in the Auto-Tires-Trucks sector that has outperformed, with a year-to-date increase of 23.8% and a Zacks Rank of 1 (Strong Buy) [5] - The Automotive - Domestic industry, to which Xos belongs, has performed better overall, with a gain of 15.6% this year [6]

Company Overview - Cemex is currently ranked 2 (Buy) in the Zacks Rank, indicating a strong earnings outlook with a 45.2% increase in the full-year earnings estimate over the past quarter [3] - The stock has gained approximately 12.4% year-to-date, outperforming the average return of 9.5% for the Construction sector [4] Industry Performance - Cemex belongs to the Building Products - Concrete and Aggregates industry, which is ranked 184 in the Zacks Industry Rank, with an average gain of 26.9% year-to-date, indicating that Cemex is slightly underperforming its industry [5] - In contrast, MasTec, another stock in the Construction sector, is part of the Building Products - Heavy Construction industry, which has seen a significant increase of 61.4% since the beginning of the year and is ranked 98 [6] Sector Context - The Construction group, which includes Cemex, is currently ranked 16 within the Zacks Sector Rank, which evaluates 16 different sector groups [2] - The Zacks Rank system focuses on earnings estimates and revisions, suggesting that stocks with improving earnings outlooks, like Cemex, are likely to outperform the market in the near term [3]